Cartesian Therapeutics (RNAC) Change in Accured Expenses (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Change in Accured Expenses data on file, last reported at -$850000.0 in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 60.97% year-over-year to -$850000.0 in Q1 2026; TTM through Mar 2026 was -$2.3 million, a 9.35% increase from a year earlier, with the FY2025 full-year figure at -$3.6 million, up 46.77% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$850000.0, down from $1.1 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for RNAC reached as high as $3.2 million in Q2 2022 and fell as low as -$6.4 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged -$689882.4 across 5 years, with a median of -$432000.0 in 2025.
• Across the five-year window, Change in Accured Expenses soared 716.67% in 2023 and slumped 222.78% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $1.6 million in 2022, then plunged by 171.21% to -$1.1 million in 2023, then surged by 203.56% to $1.2 million in 2024, then declined by 8.94% to $1.1 million in 2025, then sank by 180.26% to -$850000.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$850000.0 in Q1 2026, $1.1 million in Q4 2025, and -$432000.0 in Q3 2025.